Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1991 1
1993 2
1995 1
1996 1
1997 2
1998 2
1999 12
2000 15
2001 22
2002 37
2003 26
2004 47
2005 52
2006 58
2007 81
2008 92
2009 102
2010 76
2011 80
2012 67
2013 146
2014 82
2015 95
2016 90
2017 89
2018 77
2019 81
2020 70
2021 90
2022 82
2023 72
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,578 results

Results by year

Filters applied: . Clear all
Page 1
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER, Alibegovic AC, Corcoy R, Dunne F, Feig DS, Hod M, Jia T, Kalyanam B, Kar S, Kautzky-Willer A, Marchesini C, Rea RD, Damm P; EXPECT study group. Mathiesen ER, et al. Lancet Diabetes Endocrinol. 2023 Feb;11(2):86-95. doi: 10.1016/S2213-8587(22)00307-2. Epub 2023 Jan 6. Lancet Diabetes Endocrinol. 2023. PMID: 36623517 Clinical Trial.
In this non-inferiority trial, we aimed to compare the efficacy and safety of degludec with insulin detemir (detemir), both in combination with insulin aspart (aspart), in pregnant women with type 1 diabetes. ...Women aged at least 18 years with type 1 …
In this non-inferiority trial, we aimed to compare the efficacy and safety of degludec with insulin detemir (detemir), both in combin …
Insulin aspart.
Simpson KL, Spencer CM. Simpson KL, et al. Drugs. 1999 May;57(5):759-65; discussion 766-7. doi: 10.2165/00003495-199957050-00013. Drugs. 1999. PMID: 10353301 Review.
Insulin aspart is a recombinant analogue of human insulin. Following subcutaneous insulin injection (0.15 to 0.2 U/kg), significantly higher serum insulin concentrations are achieved in a shorter time with insulin aspart than with …
Insulin aspart is a recombinant analogue of human insulin. Following subcutaneous insulin injection (0.15 to 0.2 …
Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.
Davis A, Kuriakose J, Clements JN. Davis A, et al. Clin Pharmacokinet. 2019 Apr;58(4):421-430. doi: 10.1007/s40262-018-0696-8. Clin Pharmacokinet. 2019. PMID: 29978361 Review.
Another new product is faster insulin aspart (Fiasp, Novo Nordisk), a fast-acting insulin with 100 units/mL. Several studies have been conducted evaluating the pharmacokinetics and pharmacodynamics of faster insulin aspart, compared with insu …
Another new product is faster insulin aspart (Fiasp, Novo Nordisk), a fast-acting insulin with 100 units/mL. Several st …
Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H, Heise T. Haahr H, et al. Clin Pharmacokinet. 2020 Feb;59(2):155-172. doi: 10.1007/s40262-019-00834-5. Clin Pharmacokinet. 2020. PMID: 31667789 Free PMC article. Review.
Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previo …
Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine …
Pharmacological Properties of Faster-Acting Insulin Aspart.
Biester T, Kordonouri O, Danne T. Biester T, et al. Curr Diab Rep. 2017 Sep 23;17(11):101. doi: 10.1007/s11892-017-0931-y. Curr Diab Rep. 2017. PMID: 28940145 Review.
PURPOSE OF REVIEW: Faster aspart is a new formulation of insulin aspart (IAsp) produced by adding the excipients niacinamide and L-arginine. ...Faster aspart shows a faster occurrence of insulin in the blood compared with IAsp in subcutaneous in …
PURPOSE OF REVIEW: Faster aspart is a new formulation of insulin aspart (IAsp) produced by adding the excipients niacin …
Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
Evans M, Ceriello A, Danne T, De Block C, DeVries JH, Lind M, Mathieu C, Nørgaard K, Renard E, Wilmot EG. Evans M, et al. Diabetes Obes Metab. 2019 Sep;21(9):2039-2047. doi: 10.1111/dom.13798. Epub 2019 Jun 19. Diabetes Obes Metab. 2019. PMID: 31144428 Free PMC article. Review.
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L-arginine. The improved pharmacological profile and greater early glucose-lowering action of faster …
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the …
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Kellerer M, Kaltoft MS, Lawson J, Nielsen LL, Strojek K, Tabak Ö, Jacob S. Kellerer M, et al. Diabetes Obes Metab. 2022 Sep;24(9):1788-1799. doi: 10.1111/dom.14765. Epub 2022 Jun 29. Diabetes Obes Metab. 2022. PMID: 35546450 Free PMC article. Clinical Trial.
AIM: To compare the efficacy and safety of once-weekly (OW) semaglutide versus thrice-daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin. ...A higher proport …
AIM: To compare the efficacy and safety of once-weekly (OW) semaglutide versus thrice-daily (TID) insulin aspart (IAsp) in par …
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
Demir T, Turan S, Unluhizarci K, Topaloglu O, Tukek T, Gogas Yavuz D. Demir T, et al. Front Endocrinol (Lausanne). 2021 Mar 12;12:616514. doi: 10.3389/fendo.2021.616514. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33776914 Free PMC article. Review.
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which targets post-prandial glucose. ...The expert …
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), which prov …
Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P, Hramiak I. Senior P, et al. Can J Diabetes. 2019 Oct;43(7):515-523. doi: 10.1016/j.jcjd.2019.01.004. Epub 2019 Jan 24. Can J Diabetes. 2019. PMID: 30872107 Free article. Review.
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the excipients niacinamide and L-arginine. Faster aspart has an earlier onset of insulin exposure and a greater early glucose-low …
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the …
Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.
Hermansen K, Bohl M, Schioldan AG. Hermansen K, et al. Drugs. 2016 Jan;76(1):41-74. doi: 10.1007/s40265-015-0500-0. Drugs. 2016. PMID: 26607485 Free PMC article. Review.
As expected with this improved pharmacokinetic profile, insulin aspart demonstrates a greater glucose-lowering effect compared with regular human insulin. ...The next generation of insulin aspart (faster-acting insulin aspart) is b …
As expected with this improved pharmacokinetic profile, insulin aspart demonstrates a greater glucose-lowering effect compared …
1,578 results

Searches related to "insulin aspart"